Furthermore, liensinine at 20 μM binds to the S1 G-quadruplex structure in the fibroblast growth factor receptor 2 (FGFR2) promoter with a high affinity and selectivity, inhibiting FGFR2 expression at both the transcriptional and translational levels, providing a novel approach for breast cancer treatment [21]. The gene discussed is FGFR2; the disease is breast carcinoma.